- Prev close
- $84.46
- Day range
- $79.20 – $82.85
DexCom rose +3.0% on unusual volume while the Nasdaq 100 fell -3.5%, and the move looks more stock-specific than market-driven. The longer-term picture is mixed: 15.5% revenue growth, 22.9% operating margin, and a 31.1 P/E support the franchise, but the stock has also shown sharp swings around product and news catalysts.
DXCM
DEXCOM INC
As of Nov 1, 2026
62/100
Worth keeping an eye onHealth ScoreWhat drove the move
DexCom closed up +3.0% even as the S&P 500 fell -1.8% and the Nasdaq 100 fell -3.5%, so the session was not explained by the broader tape. The stock was also flagged among S&P 500 unusual volume movers, which points to stock-specific trading interest rather than a market-wide bounce. The recent company-specific catalyst in the facts is the CONNECT randomized controlled trial of its G7 CGM being published in The New England Journal of Medicine, which is the clearest fundamental reason for the move.
Volatility vs. fundamentals
This looks like normal-to-elevated volatility for a stock with a beta of 1.45, not a deterioration story. The business still shows 15.5% revenue growth (TTM), 13.1% latest-quarter revenue growth, and 79.4% EPS growth (TTM), with gross margin at 64.3%, operating margin at 22.9%, and net margin at 20.1%. Valuation is not cheap at a PE of 31.1 and forward PE of 26.8; the PEG of 1.39 means investors are paying 1.39 times the growth rate, so good growth is already partly priced in, which can amplify both gains and pullbacks. Against those numbers, a +3.0% move is not out of line, but it is not a sign that fundamentals have suddenly re-rated higher either.
Earnings outlook
The next earnings date is not available this period, so I cannot anchor the preview to a specific report date. The fact set also does not include analyst consensus revenue or EPS estimates, so there is no current Street forecast to quote here. What the market will likely focus on, based on the available facts, is whether the 15.5% revenue growth and 79.4% EPS growth can continue, whether margins stay near 64.3% gross, 22.9% operating, and 20.1% net, and whether the G7 clinical read-through from the NEJM publication translates into sustained adoption. The recent pattern in the facts shows the name can move sharply on stock-specific headlines, including a -6.22% decline on Oct. 21, 2026, so the next report should be read alongside any fresh product or adoption commentary.
This report is for informational and educational purposes only. It does not constitute financial, investment, tax, or legal advice. The platform does not recommend buying or selling any security.
Track DXCM with WhyIHold
Get a plain-English explanation the next time DEXCOM INC makes a big move — so you know whether it's benign or worth your attention.